PML and PML nuclear bodies: Implications in antiviral defence

Biochimie

Volumn 89, Issue 6-7, 2007, Pages 819-830

  Everett, Roger D ^a   Chelbi Alix, Mounira K ^b  

^a INSTITUTE OF VIROLOGY   (United Kingdom)

^b CNRS   (France)

Author keywords

Interferon; Promyelocytic leukaemia; Small ubiquitin modifier; Sp100; TRIM

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CELL PROTEIN; DNA; INTERFERON; PROMYELOCYTIC LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN I; PROMYELOCYTIC LEUKEMIA PROTEIN II; PROMYELOCYTIC LEUKEMIA PROTEIN III; PROMYELOCYTIC LEUKEMIA PROTEIN IV; PROMYELOCYTIC LEUKEMIA PROTEIN V; PROMYELOCYTIC LEUKEMIA PROTEIN VI; PROMYELOCYTIC LEUKEMIA PROTEIN VII; PROTEIN P53; PROTEIN SP100; SUMO PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; BIOACCUMULATION; CELL NUCLEUS INCLUSION BODY; CHROMATIN STRUCTURE; DNA REPAIR; DNA VIRUS; GENETIC TRANSCRIPTION; HOST RESISTANCE; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; RNA VIRUS; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIGENS, NUCLEAR; ANTIVIRAL AGENTS; AUTOANTIGENS; DNA; DNA REPAIR; EXONS; GENE EXPRESSION REGULATION; GENOME, VIRAL; INTERFERONS; INTRANUCLEAR INCLUSION BODIES; LEUKEMIA, PROMYELOCYTIC, ACUTE; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PROTEIN DENATURATION; PROTEIN FOLDING; RNA; TUMOR SUPPRESSOR PROTEIN P53;

DNA VIRUSES;

EID: 34347348272     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.01.004     Document Type: Review

References (137)

1. Everett R.D., Lomonte P., Sternsdorf T., van Driel R., and Orr A. Cell cycle regulation of PML modification and ND10 composition. J. Cell Sci. 112 (1999) 4581-4588
2. Dellaire G., Ching R.W., Ahmed K., Jalali F., Tse K.C., Bristow R.G., and Bazett-Jones D.P. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J. Cell Biol. 175 (2006) 55-66
3. Sternsdorf T., Grotzinger T., Jensen K., and Will H. Nuclear dots: actors on many stages. Immunobiology 198 (1997) 307-331
4. Sternsdorf T., Jensen K., and Will H. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell Biol. 139 (1997) 1621-1634
5. Dellaire G., and Bazett-Jones D.P. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26 (2004) 963-977
6. Bernardi R., and Pandolfi P.P. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22 (2003) 9048-9057
7. Bischof O., Kirsh O., Pearson M., Itahana K., Pelicci P.G., and Dejean A. Deconstructing PML-induced premature senescence. EMBO J. 21 (2002) 3358-3369
8. Anton L.C., Schubert U., Bacik I., Princiotta M.F., Wearsch P.A., Gibbs J., Day P.M., Realini C., Rechsteiner M.C., Bennink J.R., and Yewdell J.W. Intracellular localization of proteasomal degradation of a viral antigen. J. Cell Biol. 146 (1999) 113-124
9. Lallemand-Breitenbach V., Zhu J., Puvion F., Koken M., Honore N., Doubeikovsky A., Duprez E., Pandolfi P.P., Puvion E., Freemont P., and de Thé H. Role of promyelocytic leukemia (PML) simulation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193 (2001) 1361-1371
10. Regad T., and Chelbi-Alix M.K. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20 (2001) 7274-7286
11. Negorev D., and Maul G.G. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20 (2001) 7234-7242
12. Carbone R., Pearson M., Minucci S., and Pelicci P.G. PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage. Oncogene 21 (2002) 1633-1640
13. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., and Lowe S.W. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14 (2000) 2015-2027
14. Salomoni P., and Pandolfi P.P. The role of PML in tumor suppression. Cell 108 (2002) 165-170
15. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., and Pelicci P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (2000) 207-210
16. Pearson M., and Pelicci P.G. PML interaction with p53 and its role in apoptosis and replicative senescence. Oncogene 20 (2001) 7250-7256
17. Pampin M., Simonin Y., Blondel B., Percherancier Y., and Chelbi-Alix M.K. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J. Virol. 80 (2006) 8582-8592
18. Jensen K., Shiels C., and Freemont P.S. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20 (2001) 7223-7233
19. Borden K.L.B., Boddy M.N., Lally J., O'Reilly N.J., Martin S., Howe K., Solomon E., and Freemont P.S. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J. 14 (1995) 1532-1541
20. Ishov A.M., Sotnikov A.G., Negorev D., Vladimirova O.V., Neff N., Kamitani T., Yeh E.T., Strauss III J.F., and Maul G.G. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147 (1999) 221-234
21. Zhong S., Salomoni P., and Pandolfi P.P. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2 (2000) E85-E90
22. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., Pelicci P.G., and Ballabio A. The tripartite motif family identifies cell compartments. EMBO J. 20 (2001) 2140-2151
23. Beech S.J., Lethbridge K.J., Killick N., McGlincy N., and Leppard K.N. Isoforms of the promyelocytic leukemia protein differ in their effects on ND10 organization. Exp. Cell Res. 307 (2005) 109-117
24. Condemine W., Takahashi Y., Zhu J., Puvion-Dutilleul F., Guegan S., Janin A., and de Thé H. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 66 (2006) 6192-6198
25. Seeler J.S., and Dejean A. SUMO: of branched proteins and nuclear bodies. Oncogene 20 (2001) 7243-7249
26. Shen T.H., Lin H.K., Scaglioni P.P., Yung T.M., and Pandolfi P.P. The Mechanisms of PML-Nuclear Body Formation, Mol. Cell 24 (2006) 331-339
27. Best J.L., Ganiatsas S., Agarwal S., Changou A., Salomoni P., Shirihai O., Meluh P.B., Pandolfi P.P., and Zon L.I. SUMO-1 protease-1 regulates gene transcription through PML. Mol. Cell 10 (2002) 843-855
28. Kotaja N., Karvonen U., Janne O.A., and Palvimo J.J. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell. Biol. 22 (2002) 5222-5234
29. Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F., and Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 15 (2001) 3088-3103
30. Szostecki C., Guldner H., Netter H., and Will H. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies of patients with primary biliary cirrhosis. J. Immunol. 145 (1990) 4338-4347
31. Guldner H.H., Szostecki C., Schroder P., Matschl U., Jensen K., Luders C., Will H., and Sternsdorf T. Splice variants of the nuclear dot-associated Sp100 protein contain homologies to HMG-1 and a human nuclear phosphoprotein-box motif. J. Cell Sci. 112 Pt 5 (1999) 733-747
32. Bottomley M.J., Collard M.W., Huggenvik J.I., Liu Z., Gibson T.J., and Sattler M. The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation. Nat. Struct. Biol. 8 (2001) 626-633
33. Seeler J.S., Marchio A., Sitterlin D., Transy C., and Dejean A. Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc. Natl. Acad. Sci. USA 95 (1998) 7316-7321
34. Isaac A., Wilcox K.W., and Taylor J.L. SP100B, a repressor of gene expression preferentially binds to DNA with unmethylated CpGs. J. Cell Biochem. 98 (2006) 1106-1122
35. Wilcox K.W., Sheriff S., Isaac A., and Taylor J.L. SP100B is a repressor of gene expression. J. Cell Biochem. 95 (2005) 352-365
36. Negorev D.G., Vladimirova O.V., Ivanov A., Rauscher III F., and Maul G.G. Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression. J. Virol. 80 (2006) 8019-8029
37. Sternsdorf T., Jensen K., Reich B., and Will H. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J. Biol. Chem. 274 (1999) 12555-12566
38. Everett R.D., Rechter S., Papior P., Tavalai N., Stamminger T., and Orr A. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 80 (2006) 7995-8005
39. Chelbi-Alix M.K., Pelicano L., Quignon F., Koken M.H.M., Venturini L., Stadler M., Pavlovic J., Degos L., and de Thé H. Induction of the PML protein by interferons in normal and APL cells. Leukemia 9 (1995) 2027-2033
40. Stadler M., Chelbi-Alix M.K., Koken M.H.M., Venturini L., Lee C., Saïb A., Quignon F., Pelicano L., Guillemin M.-C., Schindler C., and de Thé H. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11 (1995) 2565-2573
41. Guldner H., Szostecki C., Grotzinger T., and Will H. IFN enhances expression of Sp100, an autoantigen in primary biliary cirrhosis. J. Immunol. 149 (1992) 4067-4073
42. Grötzinger T., Jensen K., and Will H. The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-g activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility. J. Biol. Chem. 271 (1996) 25253-25260
43. Fabunmi R.P., Wigley W.C., Thomas P.J., and DeMartino G.N. Interferon gamma regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. J. Cell Sci. 114 (2001) 29-36
44. Liu K.D., Gaffen S.L., and Goldsmith M.A. JAK/STAT signaling by cytokine receptors. Curr. Opin. Immunol. 10 (1998) 271-278
45. Wormald S., and Hilton D.J. Inhibitors of cytokine signal transduction. J. Biol. Chem. 279 (2004) 821-824
46. Ishov A.M., Vladimirova O.V., and Maul G.G. Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX. J. Cell Sci. 117 (2004) 3807-3820
47. Hollenbach A.D., McPherson C.J., Mientjes E.J., Iyengar R., and Grosveld G. Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J. Cell Sci. 115 (2002) 3319-3330
48. Luciani J.J., Depetris D., Usson Y., Metzler-Guillemain C., Mignon-Ravix C., Mitchell M.J., Megarbane A., Sarda P., Sirma H., Moncla A., Feunteun J., and Mattei M.G. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase. J. Cell Sci. 119 (2006) 2518-2531
49. Zhang R., Poustovoitov M.V., Ye X., Santos H.A., Chen W., Daganzo S.M., Erzberger J.P., Serebriiskii I.G., Canutescu A.A., Dunbrack R.L., Pehrson J.R., Berger J.M., Kaufman P.D., and Adams P.D. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev. Cell 8 (2005) 19-30
50. Zhong S., Hu P., Ye T.Z., Stan R., Ellis N.A., and Pandolfi P.P. A role for PML and the nuclear body in genomic stability. Oncogene 18 (1999) 7941-7947
51. Eskiw C.H., Dellaire G., and Bazett-Jones D.P. Chromatin contributes to structural integrity of promyelocytic leukemia bodies through a SUMO-1-independent mechanism. J. Biol. Chem. 279 (2004) 9577-9585
52. Ching R.W., Dellaire G., Eskiw C.H., and Bazett-Jones D.P. PML bodies: a meeting place for genomic loci?. J. Cell Sci. 118 (2005) 847-854
53. Yeager T.R., Neumann A.A., Englezou A., Huschtscha L.I., Noble J.R., and Reddel R.R. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 59 (1999) 4175-4179
54. Hay R.T. SUMO: a history of modification. Mol. Cell 18 (2005) 1-12
55. Seeler J.S., and Dejean A. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell. Biol. 4 (2003) 690-699
56. Everett R.D. Interactions between DNA viruses, ND10 and the DNA damage response. Cell Microbiol. 8 (2006) 365-374
57. Boe S.O., Haave M., Jul-Larsen A., Grudic A., Bjerkvig R., and Lonning P.E. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. J. Cell Sci. 119 (2006) 3284-3295
58. Lafarga M., Berciano M.T., Pena E., Mayo I., Castano J.G., Bohmann D., Rodrigues J.P., Tavanez J.P., and Carmo-Fonseca M. Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. Mol. Biol. Cell 13 (2002) 2771-2782
59. Dovey C.L., Varadaraj A., Wyllie A.H., and Rich T. Stress responses of PML nuclear domains are ablated by ataxin-1 and other nucleoprotein inclusions. J. Pathol. 203 (2004) 877-883
60. Fu L., Gao Y.S., Tousson A., Shah A., Chen T.L., Vertel B.M., and Sztul E. Nuclear aggresomes form by fusion of PML-associated aggregates. Mol. Biol. Cell 16 (2005) 4905-4917
61. Kumada S., Uchihara T., Hayashi M., Nakamura A., Kikuchi E., Mizutani T., and Oda M. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies. J. Neuropathol. Exp. Neurol. 61 (2002) 984-991
62. Janer A., Martin E., Muriel M.P., Latouche M., Fujigasaki H., Ruberg M., Brice A., Trottier Y., and Sittler A. PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J. Cell Biol. 174 (2006) 65-76
63. Wang Z.G., Delva L., Gaboli M., Rivi R., Giorgio M., Cordon-Cardo C., Grosveld F., and Pandolfi P.P. Role of PML in cell growth and the retinoic acid pathway. Science 279 (1998) 1547-1551
64. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., and Pandolfi P.P. PML is essential for multiple apoptotic pathways. Nat. Genet. 20 (1998) 266-272
65. Lin H.K., Bergmann S., and Pandolfi P.P. Cytoplasmic PML function in TGF-beta signalling. Nature 431 (2004) 205-211
66. Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., and Paolo Pandolfi P. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2 (2000) 730-736
67. Bonilla W.V., Pinschewer D.D., klenerman P., Rousson V., Gaboli M., Pandolfi P., Zinkernagel R.M., Salvato M.S., and Hengartner H. Effects of promyelocytic leukemia protein on virus-host balance. J. Virol. 76 (2002) 3810-3818
68. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T., Honda K., and Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (2003) 516-523
69. Porta C., Hadj-Slimane R., Nejmeddine M., Pampin M., Tovey M.G., Espert L., Alvarez S., and Chelbi-Alix M.K. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene 24 (2005) 605-615
70. Fogal V., Gostissa M., Sandy P., Zacchi P., Sternsdorf T., Jensen K., Pandolfi P.P., Will H., Schneider C., and Del Sal G. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19 (2000) 6185-6195
71. Rodriguez M.S., Desterro J.M., Lain S., Midgley C.A., Lane D.P., and Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18 (1999) 6455-6461
72. Kwek S.S., Derry J., Tyner A.L., Shen Z., and Gudkov A.V. Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 20 (2001) 2587-2599
73. Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A., Snowden A.W., Garcia-Wilson E., Perkins N.D., and Hay R.T. P300 transcriptional repression is mediated by SUMO modification. Mol. Cell 11 (2003) 1043-1054
74. Kim Y.H., Choi C.Y., and Kim Y. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1. Proc. Natl. Acad. Sci. USA 96 (1999) 12350-12355
75. Goodbourn S., Didcock L., and Randall R.E. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81 (2000) 2341-2364
76. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
77. Chelbi-Alix M.K., Vidy A., El Bougrini J., and Blondel D. Rabies viral mechanisms to escape the IFN system: the viral protein P interferes with IRF-3, Stat1, and PML nuclear bodies. J. Interferon Cytokine Res. 26 (2006) 271-280
78. Rolley N., Butcher S., and Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 11 (1995) 763-770
79. Regad T., Saib A., Lallemand-Breitenbach V., Pandolfi P.P., de Thé H., and Chelbi-Alix M.K. PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO J. 20 (2001) 3495-3505
80. Chelbi-Alix M.K., Quignon F., Pelicano L., Koken M.H.M., and de Thé H. Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J. Virol. 72 (1998) 1043-1051
81. Iki S., Yokota S., Okabayashi T., Yokosawa N., Nagata K., and Fujii N. Serum-dependent expression of promyelocytic leukemia protein suppresses propagation of influenza virus. Virology 343 (2005) 106-115
82. Engelhardt O.G., Sirma H., Pandolfi P.P., and Haller O. Mx1 GTPase accumulates in distinct nuclear domains and inhibits influenza A virus in cells that lack promyelocytic leukaemia protein nuclear bodies. J. Gen. Virol. 85 (2004) 2315-2326
83. Blondel D., Regad T., Poisson N., Pavie B., Harper F., Pandolfi P.P., De Thé H., and Chelbi-Alix M.K. Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies. Oncogene 21 (2002) 7957-7970
84. Djavani M., Rodas J., Lukashevich I.S., Horejsh D., Pandolfi P.P., Borden K.L., and Salvato M.S. Role of the promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J. Virol. 75 (2001) 6204-6208
85. Asper M., Sternsdorf T., Hass M., Drosten C., Rhode A., Schmitz H., and Gunther S. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J. Virol. 78 (2004) 3162-3169
86. Zhu J., Koken M.H., Quignon F., Chelbi-Alix M.K., Degos L., Wang Z.Y., Chen Z., and de Thé H. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94 (1997) 3978-3983
87. Weber F., Kochs G., and Haller O. Inverse interference: how viruses fight the interferon system. Viral Immunol. 17 (2004) 498-515
88. Sharma R., Raychaudhuri S., and Dasgupta A. Nuclear entry of poliovirus protease-polymerase precursor 3CD: implications for host cell transcription shut-off. Virology 320 (2004) 195-205
89. Weidman M.K., Yalamanchili P., Ng B., Tsai W., and Dasgupta A. Poliovirus 3C protease-mediated degradation of transcriptional activator p53 requires a cellular activity. Virology 291 (2001) 260-271
90. Chenik M., Schnell M., Conzelmann K.K., and Blondel D. Mapping the interacting domains between the rabies virus polymerase and phosphoprotein. J. Virol. 72 (1998) 1925-1930
91. Jacob Y., Real E., and Tordo N. Functional interaction map of lyssavirus phosphoprotein: identification of the minimal transcription domains. J. Virol. 75 (2001) 9613-9622
92. Brzozka K., Finke S., and Conzelmann K.K. Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J. Virol. 79 (2005) 7673-7681
93. Vidy A., Chelbi-Alix M., and Blondel D. Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J. Virol. 79 (2005) 14411-14420
94. Borden K., Campbell-Dwyer E.J., Carlile G., Djavani M., and Salvato M. Two RING finger proteins, the oncoprotein PML and the arenavirus Z protein, colocalize with the nuclear fraction of the ribosomal P proteins. J. Virol. 72 (1998) 3819-3826
95. Martinez-Sobrido L., Zuniga E.I., Rosario D., Garcia-Sastre A., and de la Torre J.C. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 80 (2006) 9192-9199
96. Bartenschlager R., Kaul A., and Sparacio S. Replication of the hepatitis C virus in cell culture. Antiviral Res. 60 (2003) 91-102
97. Herzer K., Weyer S., Krammer P.H., Galle P.R., and Hofmann T.G. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res. 65 (2005) 10830-10837
98. Rouille Y., Helle F., Delgrange D., Roingeard P., Voisset C., Blanchard E., Belouzard S., McKeating J., Patel A.H., Maertens G., Wakita T., Wychowski C., and Dubuisson J. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J. Virol. 80 (2006) 2832-2841
99. Everett R.D. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20 (2001) 7266-7273
100. Maul G.G. Nuclear domain 10, the site of DNA virus transcription and replication. Bioessays 20 (1998) 660-667
101. Maul G.G., Ishov A.M., and Everett R.D. Nuclear domain 10 as preexisting potential replication start sites of herpes simplex virus type-1. Virology 217 (1996) 67-75
102. Ishov A.M., and Maul G.G. The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition. J. Cell Biol. 134 (1996) 815-826
103. Wiesmeijer K., Molenaar C., Bekeer I.M., Tanke H.J., and Dirks R.W. Mobile foci of Sp100 do not contain PML: PML bodies are immobile but PML and Sp100 proteins are not. J. Struct. Biol. 140 (2002) 180-188
104. Everett R.D., and Murray J. ND10 Components relocate to sites associated with herpes simplex virus type 1 nucleoprotein complexes during virus infection. J. Virol. 79 (2005) 5078-5089
105. Bell P., Lieberman P.M., and Maul G.G. Lytic but not latent replication of Epstein-Barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins. J. Virol. 74 (2000) 11800-11810
106. Smith A.E., and Helenius A. How viruses enter animal cells. Science 304 (2004) 237-242
107. Fraefel C., Bittermann A.G., Bueler H., Heid I., Bachi T., and Ackermann M. Spatial and temporal organization of adeno-associated virus DNA replication in live cells. J. Virol. 78 (2004) 389-398
108. Doucas V., Ishov A.M., Romo A., Juguilon H., Weitzman M.D., Evans R.M., and Maul G.G. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10 (1996) 196-207
109. Hoppe A., Beech S.J., Dimmock J., and Leppard K.N. Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J. Virol. 80 (2006) 3042-3049
110. Carson C.T., Schwartz R.A., Stracker T.H., Lilley C.E., Lee D.V., and Weitzman M.D. The Mre11 complex is required for ATM activation and the G2/M checkpoint. EMBO J. 22 (2003) 6610-6620
111. Stracker T.H., Lee D.V., Carson C.T., Araujo F.D., Ornelles D.A., and Weitzman M.D. Serotype-specific reorganization of the Mre11 complex by adenoviral E4orf3 proteins. J. Virol. 79 (2005) 6664-6673
112. Boutell C., Sadis S., and Everett R.D. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J. Virol. 76 (2002) 841-850
113. Hagglund R., and Roizman B. Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1. J. Virol. 78 (2004) 2169-2178
114. Everett R.D. ICP0, a regulator of herpes simplex virus during lytic and latent infection. Bioessays 22 (2000) 761-770
115. Parkinson J., and Everett R.D. Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J. Virol. 74 (2000) 10006-10017
116. Saffert R.T., and Kalejta R.F. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. J. Virol. 80 (2006) 3863-3871
117. Kang H., Kim E.T., Lee H.R., Park J.J., Go Y.Y., Choi C.Y., and Ahn J.H. Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein. J. Gen. Virol. 87 (2006) 2181-2190
118. Ahn J.H., and Hayward G.S. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology 274 (2000) 39-55
119. Ling P.D., Peng R.S., Nakajima A., Yu J.H., Tan J., Moses S.M., Yang W.H., Zhao B., Kieff E., Bloch K.D., and Bloch D.B. Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J. 24 (2005) 3565-3575
120. Chelbi-Alix M.K., and de Thé H. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18 (1999) 935-941
121. Lopez P., Jacob R.J., and Roizman B. Overexpression of promyelocytic leukemia protein precludes the dispersal of ND10 structures and has no effect on accumulation of infectious herpes simplex virus 1 or its proteins. J. Virol. 76 (2002) 9355-9367
122. Chee A.V., Lopez P., Pandolfi P.P., and Roizman B. Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J. Virol. 77 (2003) 7101-7105
123. Cantrell S.R., and Bresnahan W.A. Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression of HCMV replication. J. Virol. 80 (2006) 6188-6191
124. Preston C.M., and Nicholl M.J. Role of the cellular protein hDaxx in human cytomegalovirus immediate-early gene expression. J. Gen. Virol. 87 (2006) 1113-1121
125. Tavalai N., Papior P., Rechter S., Leis M., and Stamminger T. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 80 (2006) 8006-8018
126. Harle P., Sainz Jr. B., Carr D.J., and Halford W.P. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/beta. Virology 293 (2002) 295-304
127. Mossman K.L., Saffran H.A., and Smiley J.R. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J. Virol. 74 (2000) 2052-2056
128. Eidson K.M., Hobbs W.E., Manning B.J., Carlson P., and DeLuca N.A. Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection. J. Virol. 76 (2002) 2180-2191
129. Henderson G., Zhang Y., and Jones C. The Bovine herpesvirus 1 gene encoding infected cell protein 0 (bICP0) can inhibit interferon-dependent transcription in the absence of other viral genes. J. Gen. Virol. 86 (2005) 2697-2702
130. Brukman A., and Enquist L.W. Pseudorabies virus EP0 protein counteracts an interferon-induced antiviral state in a species-specific manner. J. Virol. 80 (2006) 10871-10873
131. Halford W.P., Weisend C., Grace J., Soboleski M., Carr D.J., Balliet J.W., Imai Y., Margolis T.P., and Gebhardt B.M. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol. J. 3 (2006) 44
132. Preston C.M., Harman A.N., and Nicholl M.J. Activation of interferon response factor-3 in human cells infected with herpes simplex virus type 1 or human cytomegalovirus. J. Virol. 75 (2001) 8909-8916
133. Mossman K.L., Macgregor P.F., Rozmus J.J., Goryachev A.B., Edwards A.M., and Smiley J.R. Herpes simplex virus triggers and then disarms a host antiviral response. J. Virol. 75 (2001) 750-758
134. Melroe G.T., DeLuca N.A., and Knipe D.M. Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J. Virol. 78 (2004) 8411-8420
135. Bishop C.L., Ramalho M., Nadkarni N., May Kong W., Higgins C.F., and Krauzewicz N. Role for centromeric heterochromatin and PML nuclear bodies in the cellular response to foreign DNA. Mol. Cell. Biol. 26 (2006) 2583-2594
136. Paulus C., Krauss S., and Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. USA 103 (2006) 3840-3845
137. Everett R.D., Boutell C., and Orr A. Phenotype of a herpes simplex virus type 1 mutant that fails to express immediate-early regulatory protein ICP0. J. Virol. 78 (2004) 1763-1774